NCT06475443View on ClinicalTrials.gov

Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

January 31, 2027

Conditions

Metastatic Breast Cancer in the Brain

Interventions

DRUG

pyrotinib plus capecitabine

oral

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV